Unnamed stage
Our 4th newsletter detailing our investment in Qubigen
Synthesis BioVentures' fourth newsletter covers its backing of Qubigen; the captured page holds only a title and date, with no further detail.
VC firm blog
Synthesis BioVentures
Everything we hold that Synthesis BioVentures published.
Articles
Every article we hold from Synthesis BioVentures.
News
Andrew Wilks Wins the Prime Minister's Award
Cytopia founder Andrew Wilks and Chris Burns won the 2024 Prime Minister's Prize for Innovation for inventing momelotinib, a rare blood-cancer drug the US FDA approved in 2023.
Unnamed stage
~$7.5m
SYNthesis BioVentures Newsletter no. 3
SYNthesis BioVentures' third investor letter reports a roughly A$7.5m first close for Alzheimer's biotech S2N, lists co-investors, and profiles managing director Amir's career across OneVentures, Ceres Capital and other life-sciences roles.
Fund close
$30m
Andrew Wilks in Weekend Australian
Profile of scientist-entrepreneur Andrew Wilks tracing his path from cancer research to founding drug developer Cytopia and launching SYNthesis BioVentures, a therapeutics fund that recently secured $30 million from wealthy individuals and family offices.
2 deals
The Australian Business Review, S2N term sheet
Sydney biotech Skin2Neuron raised $4 million from SYNthesis BioVentures to develop a hair-follicle cell therapy for Alzheimer's, while the investor reached the first $20 million close of its $75 million bioscience fund.
Also SmartCompany
Fund close
$20m
Scientist behind Australia’s highest-priced molecule reveals how to profit from early stage biotechs
Biotech scientist Andrew Wilks launches fund SYNthesis BioVentures, which has gathered $20m and aims for $75m; his group has backed two biotech startups and he earlier sold a chemistry business to Viva Biotech.
Unnamed stage
$2.2m
SYNthesis BioVentures Newsletter no. 2
The venture firm's newsletter records a A$2.25m SAFE investment in Aculeus Therapeutics, its fund's second deal, and outlines the immunology-oncology pipeline and long-standing individual backers behind the biotech.
2 deals
SYNthesis BioVentures - Newsletter no. 1
Debut quarterly letter from SYNthesis BioVentures reporting A$18 million committed to its fund, an A$3.8 million stake in Catalyst Therapeutics' A$11.7 million seed round, and two senior appointments from the SYNthesis Group.
Rounds reported
Deals recorded from Synthesis BioVentures's coverage. A round is listed once, however many of their articles mention it.
| Company | Stage | Announced | Amount | Investors |
|---|---|---|---|---|
| Skin2Neuron | Unnamed stage | 9 Apr 2024 | $4m |
Companies covered
Companies named in Synthesis BioVentures's articles, most-covered first.
| Company | What it does | Articles |
|---|---|---|
| Anaxis Pharma | Targets cell death in diabetic kidney disease | 1 |
| BiVACOR | 1 | |
| Catalyst Therapeutics | 1 | |
| Ceres Capital | 1 | |
| Clinical Genomics | 1 | |
| Hatchtech | Developing a new treatment for head lice | 1 |
| KPMG | Professional services firm | 1 |
| Ludwig Institute for Cancer Research | 1 | |
| Madorra | 1 | |
| OneVentures | 1 | |
| Prota | 1 | |
| Qubigen | 1 | |
| Royal Melbourne Hospital | 1 | |
| Skin2Neuron | Develops cell therapy to reverse Alzheimer's disease by restoring neurons | 1 |
| St. Vincent's Hospital | 1 | |
| SYNthesis Med Chem | 1 | |
| SYNthesis Research | 1 | |
| The University of Sydney | 1 | |
| University of Melbourne | University operating the Melbourne Connect innovation precinct | 1 |
| University of Sydney | 1 | |
| US Food and Drug Administration | 1 | |
| Cytopia | 2 | |
| GSK | 2 | |
| Merck | 2 | |
| Pfizer | 2 | |
| Servier | 2 | |
| Aculeus Therapeutics Pty Ltd | 3 | |
| SYNthesis Group | 3 |
Investors covered
Investors named in Synthesis BioVentures's articles, most-covered first.
| Investor | What it does | Articles |
|---|---|---|
| SYNthesis BioVentures | 7 | |
| Artesian VC | Alternative asset management for debt and venture capital | 1 |
| WEHI | Medical research institute partnering on the Jumar Bioincubator grant | 1 |